Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $829.45 million for the year ending 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +23,258.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from ARROWHEAD PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on November 25, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), ARROWHEAD PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 2,540.9%.
- Historical annual values: Fiscal year 2025: $829.45 million | Fiscal year 2024: $3.55 million | Fiscal year 2023: $240.74 million | Fiscal year 2022: $243.23 million | Fiscal year 2021: $138.29 million | Fiscal year 2020: $87.99 million | Fiscal year 2019: $168.80 million | Fiscal year 2018: $16.14 million | Fiscal year 2017: $31.41 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: